CadmiumCADNATNCT07855237
Cadmium Exposure During Pregnancy and Fetal Growth
An observational study of Cadmium and Placenta, run by Centre Hospitalier Universitaire, Amiens at 1 site in France.
Trial summary
Cadmium is a toxic heavy metal naturally present in the environment, whose human exposure has increased over recent decades due to diffuse anthropogenic contamination, particularly related to industrial activities and the use of mineral phosphate fertilizers in agriculture. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Cadmium, Placenta, Fetal Growth
- What is being tested?
- maternal blood samples, Placental tissue samples and maternal urine samples
- How many people
- 50 participants
- Where
- 1 siteFrance
- Study dates
- 21 Sep 2026to Dec 2026
- How long will I take part?
- 2 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: Women delivering at term or preterm who are patients at Amiens University Hospital,
Who may be able to join
- Pregnant women aged 18 years or older
- Singleton pregnancy
- Planned delivery at the maternity unit of Amiens University Hospital (CHU Amiens)
- Ability to receive study information and provide informed non-opposition/consent according to French regulations for non-interventional research
Who cannot join
- Women under legal protection measures, including guardianship, curatorship, or judicial safeguard
- Inability to understand the study objectives or the constraints of the protocol (language barrier, cognitive impairment, or other reasons)
- Lack of affiliation to a social security system, as required by French regulations
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
CHU Amiens Picardie
Amiens
Rosalie Cabry, Pr, Cabry.Rosalie@chu-amiens.fr
Fabrice Sergent, Pr
About this study
Cadmium is a toxic heavy metal naturally present in the environment, whose human exposure has increased over recent decades due to diffuse anthropogenic contamination, particularly related to industrial activities and the use of mineral phosphate fertilizers in agriculture.
Cadmium is characterized by its bioaccumulative properties and well-established toxicity, including renal and bone damage and carcinogenic effects. In pregnant women, several animal and human cohort studies have shown that cadmium can cross the placental barrier and accumulate in placental tissue. Placental cadmium exposure has been associated with impaired placental function and adverse perinatal outcomes, including fetal growth restriction and increased neonatal morbidity. In the general population without occupational exposure, diet represents the main source of cadmium exposure, apart from tobacco smoking. Fetal growth, commonly assessed through birth weight adjusted for gestational age, is a major determinant of neonatal and long-term health outcomes. This monocentric prospective pilot study aims to assess fetal exposure to cadmium during pregnancy using placental cadmium concentration as a biomarker. Placental samples will be collected at delivery from women giving birth at Amiens University Hospital, and cadmium levels will be measured using inductively coupled plasma mass spectrometry. The association between placental cadmium concentration and fetal growth will be explored. Fetal growth will be evaluated using birth weight adjusted for gestational age, expressed as a standardized z-score. Maternal urinary and blood cadmium concentrations will also be measured to characterize maternal exposure and explore correlations between biological matrices. Placental efficiency, defined as the fetal-to-placental weight ratio, will be assessed as an indicator of placental function. The results of this pilot study will provide preliminary data to inform future larger-scale epidemiological and mechanistic studies on prenatal cadmium exposure and pregnancy outcomes.
- Conditions
- Cadmium, Placenta, Fetal Growth, Birth Weight, Environmental Exposure, Biomonitoring
- Being tested
- maternal blood samples, Placental tissue samples, maternal urine samples
- Keywords
- biomonitoring, environmental exposure, birth weight, fetal growth, Placenta, Cadmium
- Medical subject headings
- Birth Weight
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
maternal blood samplesOther
maternal blood samples are collected at admission for delivery as part of standard obstetric care.
Placental tissue samplesOther
Placental tissue samples are collected at delivery,
maternal urine samplesOther
maternal urine samples are obtained during routine prenatal visits,
What is being measured
The primary outcome is the main question the study is designed to answer.
association between placental cadmium levels and fetal growth
investigate the association between placental cadmium levels and fetal growth.
Measured: at 2 months
Secondary outcomes (4)
Association between maternal urinary cadmium concentration and fetal growth
Association between maternal urinary cadmium concentration (adjusted for creatinine) and fetal growth, assessed by birth weight adjusted for gestational age (z-score).
Measured: at 2 months
Association between maternal blood cadmium concentration and fetal growth
Association between maternal blood cadmium concentration and fetal growth, assessed by birth weight adjusted for gestational age (z-score).
Measured: at 2 months
Association between placental cadmium concentration and placental efficiency
Association between placental cadmium concentration and placental efficiency, defined as the fetal-to-placental weight ratio
Measured: at 2 months
Association between maternal dietary patterns and estimated dietary cadmium intake and cadmium concentrations measured in placental tissue
Association between maternal dietary patterns and estimated dietary cadmium intake and cadmium concentrations measured in placental tissue
Measured: at 2 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Oct 2026
- Study start21 Sep 2026
- Primary completionNov 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CadmiumStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
- Target duration
- 2 Months
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire, Amiens
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07855237
- Sponsor's protocol ID
- PI2026_843_0075
- Acronym
- CADNAT
- Status last verified
- Sep 2026
- First submitted
- 28 Sep 2026
- Last updated
- 2 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cadmium Exposure During Pregnancy and Fetal Growth
- ClinicalTrials.gov ID
- NCT07855237
- Acronym / sponsor ID
- CADNAT / PI2026_843_0075
- Conditions
- Cadmium, Placenta, Fetal Growth, Birth Weight, Environmental Exposure, Biomonitoring
- Keywords
- biomonitoring, environmental exposure, birth weight, fetal growth, Placenta, Cadmium
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Centre Hospitalier Universitaire, AmiensUniversity, hospital or other
- Study start
- 21 Sep 2026 (actual)
- Primary completion
- Nov 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 2 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cadmium is a toxic heavy metal naturally present in the environment, whose human exposure has increased over recent decades due to diffuse anthropogenic contamination, particularly related to industrial activities and the use of mineral phosphate fertilizers in agriculture.
Cadmium is characterized by its bioaccumulative properties and well-established toxicity, including renal and bone damage and carcinogenic effects. In pregnant women, several animal and human cohort studies have shown that cadmium can cross the placental barrier and accumulate in placental tissue. Placental cadmium exposure has been associated with impaired placental function and adverse perinatal outcomes, including fetal growth restriction and increased neonatal morbidity. In the general population without occupational exposure, diet represents the main source of cadmium exposure, apart from tobacco smoking. Fetal growth, commonly assessed through birth weight adjusted for gestational age, is a major determinant of neonatal and long-term health outcomes. This monocentric prospective pilot study aims to assess fetal exposure to cadmium during pregnancy using placental cadmium concentration as a biomarker. Placental samples will be collected at delivery from women giving birth at Amiens University Hospital, and cadmium levels will be measured using inductively coupled plasma mass spectrometry. The association between placental cadmium concentration and fetal growth will be explored. Fetal growth will be evaluated using birth weight adjusted for gestational age, expressed as a standardized z-score. Maternal urinary and blood cadmium concentrations will also be measured to characterize maternal exposure and explore correlations between biological matrices. Placental efficiency, defined as the fetal-to-placental weight ratio, will be assessed as an indicator of placental function. The results of this pilot study will provide preliminary data to inform future larger-scale epidemiological and mechanistic studies on prenatal cadmium exposure and pregnancy outcomes.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Target follow-up
- 2 Months
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Women delivering at term or preterm who are patients at Amiens University Hospital,
Key inclusion criteria (4 listed)
- Pregnant women aged 18 years or older
- Singleton pregnancy
- Planned delivery at the maternity unit of Amiens University Hospital (CHU Amiens)
- Ability to receive study information and provide informed non-opposition/consent according to French regulations for non-interventional research
Key exclusion criteria (3 listed)
- Women under legal protection measures, including guardianship, curatorship, or judicial safeguard
- Inability to understand the study objectives or the constraints of the protocol (language barrier, cognitive impairment, or other reasons)
- Lack of affiliation to a social security system, as required by French regulations
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| maternal blood samplesmaternal blood samples are collected at admission for delivery as part of standard obstetric care. | Other | – |
| Placental tissue samplesPlacental tissue samples are collected at delivery, | Other | – |
| maternal urine samplesmaternal urine samples are obtained during routine prenatal visits, | Other | – |
Primary outcome
association between placental cadmium levels and fetal growth
Time frame: at 2 months
investigate the association between placental cadmium levels and fetal growth.
4 secondary outcomes
Association between maternal urinary cadmium concentration and fetal growth
Time frame: at 2 months
Association between maternal blood cadmium concentration and fetal growth
Time frame: at 2 months
Association between placental cadmium concentration and placental efficiency
Time frame: at 2 months
Association between maternal dietary patterns and estimated dietary cadmium intake and cadmium concentrations measured in placental tissue
Time frame: at 2 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Cadmium
Enrolling by invitationObservational study
Assessing Toxic Metal Exposure From Vegetarian/Vegan, Omnivorous, and Low-carb Diets in Israel.
Environmental Exposure; Dietary Patterns; Nutritional Epidemiology; Human Biomonitoring
RecruitingPhase 2
The Safety and Efficacy of GMDTC for Injection in Subjects With Elevated Cadmium Levels
Cadmium Exceeds the Standard
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cadmium and Placenta, run by Centre Hospitalier Universitaire, Amiens at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Rosalie CABRY, Pr (33+3 22 08 73 70, cabry.rosalie@chu-amiens.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
association between placental cadmium levels and fetal growth (time frame: at 2 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2026.